Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis

International Ophthalmology

Volumn 34, Issue 3, 2014, Pages 465-476

  Li, Wenchang ^a   He, Bing ^b   Dai, Wenbing ^b   Zhang, Qiang ^b   Liu, Yuling ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Intraocular; Lipopolysaccharide; Microspheres; Triamcinolone acetonide; Uveitis

Indexed keywords

GLYCOLIC ACID; LIPOPOLYSACCHARIDE; MICROSPHERE; POLYLACTIC ACID; TRIAMCINOLONE ACETONIDE; ANTIINFLAMMATORY AGENT; DRUG CARRIER; GLYCOLIC ACID DERIVATIVE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; EVAPORATION; EXPERIMENTAL UVEITIS; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE COUNT; MICROENCAPSULATION; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PROTEIN DETERMINATION; RABBIT MODEL; STRUCTURE ANALYSIS; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; ANALYSIS OF VARIANCE; ANIMAL; INTRAVITREAL DRUG ADMINISTRATION; PATHOLOGY; RABBIT; UVEITIS;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; GLYCOLATES; INTRAVITREAL INJECTIONS; LACTIC ACID; MICROSPHERES; POLYGLYCOLIC ACID; POLYMERS; RABBITS; TRIAMCINOLONE ACETONIDE; UVEITIS;

EID: 84904177528     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-013-9829-0     Document Type: Article

References (35)

1. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509-516 (Pubitemid 41224845)
2. Suttorp-Schulten MS, Rothova A (1996) The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80(9):844-848 (Pubitemid 26345317)
3. Smith JR (2004) Management of uveitis. Clin Exp Med 4(1):21-29
4. Chin HS, Park TS, Moon YS et al (2005) Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and non-vitrectomized eyes. Retina 25(5): 556-560
5. Martidis A, Duker JS, Greenberg PB et al (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109(5):920-927 (Pubitemid 34465226)
6. Cunningham MA, Edelman JL, Kaushal S (2008) Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol 53(2):139-149 (Pubitemid 351391933)
7. Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110(8):1517-1525 (Pubitemid 36962483)
8. Kok H, Lau C, Maycock N et al (2005) Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112(11): 1916 e1911-1917
9. Gilger BC, Malok E, Stewart T et al (2000) Long-term effect on the equine eye of an intravitreal device used for sustained release of cyclosporine A. Vet Ophthalmol 3(2-3):105-110
10. Jermak CM, Dellacroce JT, Heffez J et al (2007) Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 52(5):503-522 (Pubitemid 47268546)
11. Salvolini E, Neri P, Orciani M, Di Primio R, Giovannini A (2008) Intravitreal micronized triamcinolone versus triamcinolone acetonide: a clinical and morphological comparative study. Int J Immunopathol Pharmacol 21(1):181-188 (Pubitemid 351501014)
12. Haghjou N, Soheilian M, Abdekhodaie MJ (2011) Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res 6(4):317-329
13. Delie F, Blanco-Prieto MJ (2005) Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 10(1):65-80 (Pubitemid 40404886)
14. Barratt GM (2000) Therapeutic applications of colloidal drug carriers. Pharm Sci Technol Today 3(5):163-171
15. Washington C (1996) Drug release from microparticulate systems. In: Benita S (ed) Microencapsulation: methods and industrial applications. Marcel Dekker, New York, pp 155-181
16. Sy JC, Davis ME (2010) Delivering regenerative cues to the heart: cardiac drug delivery by microspheres and peptide nanofibers. J Cardiovasc Transl Res 3(5):461-468
17. Bhardwaj U, Papadimitrakopoulos F, Burgess DJ (2008) A review of the development of a vehicle for localized and controlled drug delivery for implantable biosensors. J Diabetes Sci Technol 2(6):1016-1029
18. Mansoor S, Kuppermann BD, Kenney MC (2009) Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res 26(4):770-784
19. Herrero-Vanrell R, Refojo MF (2001) Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev 52(1):5-16 (Pubitemid 32973634)
20. Vallelado AI, Lopez MI, Calonge M et al (2002) Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection in rats. Curr Eye Res 24(1):39-45 (Pubitemid 34765360)
21. Khaled KA, Sarhan HA, Ibrahim MA et al (2010) Prednisolone-loaded PLGA microspheres. in vitro characterization and in vivo application in adjuvant-induced arthritis in mice. AAPS Pharm Sci Tech 11(2):859-869
22. Koga T, Koshiyama Y, Gotoh T et al (2002) Coinduction of nitric oxide synthase and arginine metabolic enzymes in endotoxin-induced uveitis rats. Exp Eye Res 75(6):659-667 (Pubitemid 36034630)
23. Hanashiro RK, Fujino Y, Gugunfu et al (1997) Synthetic lipid A-induced uveitis and endotoxin-induced uveitis - a comparative study. Jpn J Ophthalmol 41(6):355-361 (Pubitemid 28097384)
24. Rosenbaum JT, McDevitt HO, Guss RB et al (1980) Endotoxin-induced uveitis in rats as a model for human disease. Nature 286(5773):611-613 (Pubitemid 10015368)
25. Hoekzema R, Murray PI, van Haren MA et al (1991) Analysis of interleukin-6 in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 32(1):88-95
26. Cheng CK, Berger AS, Pearson PA et al (1995) Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci 36(2): 442-453
27. Barcia E, Herrero-Vanrell R, Diez A et al (2009) Down-regulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp Eye Res 89(2):238-245
28. Cardillo JA, Souza-Filho AA, & Oliveira AG (2006) Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema. Arch Soc Esp Oftalmol 81(12):675-677, 679-681
29. Siepmann J, Faisant N, Akiki J et al (2004) Effect of the size of biodegradable microparticles on drug release: experiment and theory. J Control Release 96(1):123-134 (Pubitemid 38438495)
30. Zarei-Ghanavati S, Malaekeh-Nikouei B, Pourmazar R et al (2012) Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration. J Ocul Pharmacol Ther 28(5):502-506
31. Yasukawa T, Ogura Y, Tabata Y et al (2004) Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 23(3):253-281 (Pubitemid 38737129)
32. Herrero-Vanrell R, Ramirez L, Fernandez-Carballido A et al (2000) Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. Pharm Res 17(10):1323-1328
33. Leeds JM, Henry SP, Truong L et al (1997) Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab Dispos 25(8):921-926 (Pubitemid 27357689)
34. Howes EL Jr, Morrison DC (1980) Lipid A dependence of the ocular response to circulating endotoxin in rabbits. Infect Immun 30(3):786-790
35. Beer PM, Wong SJ, Schartman JP et al (2010) Infliximab stability after reconstitution, dilution, and storage under refrigeration. Retina 30(1):81-84